Cost-utility analysis for advanced breast cancer therapy in Germany: Results of the fulvestrant sequencing model

Breast Cancer Research and Treatment

Volumn 117, Issue 2, 2009, Pages 305-317

  Lux, Michael Patrick ^a   Hartmann, M ^b   Jackisch, C ^c   Raab, G ^d   Schneeweiss A ^e   Possinger, K ^f   Oyee, J ^g   Harbeck, N ^h  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c Klinikum Offenbach GmbH   (Germany)

^d Frauenarztpaxis Mit Schwerpunkt Gynäkologische Operationen und Brustkrebschirurgie   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f FREIE UNIVERSITÄT BERLIN   (Germany)

^g MAPI VALUES   (United States)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Breast cancer; Cost effectiveness; Fulvestrant

Indexed keywords

ANASTROZOLE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; EXEMESTANE; FULVESTRANT; HORMONE RECEPTOR; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG EFFICACY; FEMALE; GERMANY; HEALTH CARE COST; HUMAN; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; POSTMENOPAUSE; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; ESTRADIOL; FEMALE; GERMANY; HUMANS; MARKOV CHAINS; QUALITY-ADJUSTED LIFE YEARS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 68949131285     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0294-9     Document Type: Article

References (42)

1. Porzsolt F, Klinische Ökonomik (2003) Die ökonomische Bewertung von Gesundheitsleistungen aus der Sicht des Patienten. In: Porzsolt F, Williams AR, Kaplan RM, Klinische Ökonomik (eds) Effektivität und Effizienz von Gesundheitsleistungen. Ecomed, Landsberg, pp 17-40
2. Health and Health Care 2010 (2000) The forecast, the challenge by the Institute for the Future. Jossey-Bass, San Francisco, CA, ISBN 0-7879-5348-2
3. National Institute for Clinical Excellence (NICE) (2008) http://www.nice.org.uk
4. Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (2008) http://www.iqwig.de/index.2.en.html
5. Federal Ministry of Health (Bundesgesundheitsministerium, BMG FHM (2008) http://www.bmg.bund.de/cln-041/DE/Home/homepage-node.html-nnn=true
6. S Beslija J Bonneterre H Burstein V Cocquyt M Gnant P Goodwin 2007 Second consensus on medical treatment of metastatic breast cancer Ann Oncol 18 2 215 225
7. AGO Guideline (2008) http://www.ago-online.de/index/php?lang=de&sote= mamma-guide08-1-1&topic=mamma-guide
8. WR Simons D Jones A Buzdar 2003 Cost-effectiveness of anastrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer Clin Ther 25 11 2972 2985
9. BR Schackman HT Gold PW Stone PJ Neumann 2004 How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions? Pharmacoeconomics 22 5 293 300
10. A Briggs M Sculpher 1998 An introduction to Markov modelling for economic evaluation Pharmacoeconomics 13 4 397 409
11. FA Sonnenberg JR Beck 1993 Markov models in medical decision making: a practical guide Med Decis Making 13 322 338
12. R DerSimonian N Laird 1986 Meta-analysis in clinical trials Control Clin Trials 7 3 177 188
13. C Rose O Vtoraya A Pluzanska N Davidson M Gershanovich R Thomas 2003 An open randomised trial of second-line endocrine therapy in advanced breast cancer comparison of the aromatase inhibitors letrozole and anastrozole Eur J Cancer 39 16 2318 2327
14. JM Nabholtz C Falkson D Campos J Szanto M Martin S Chan 2003 Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial J Clin Oncol 21 6 968 975
15. Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M (2008) Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 26(10):1664-1670
16. PE Lønning E Bajetta R Murray M Tubiana-Hulin PD Eisenberg E Mickiewicz L Celio P Pitt M Mita NK Aaronson C Fowst A Arkhipov E di Salle A Polli G Massimini 2000 Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial J Clin Oncol 18 11 2234 2244
17. B Thurlimann D Hess D Koberle I Senn P Ballabeni O Pagani 2004 Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) Breast Cancer Res Treat 85 3 247 254
18. A Buzdar D Hayes A El-Khoudary S Yan P Lønning M Lichinitser 2001 Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer Am Soc Clin Oncol 19 3357 3366
19. T Tominaga I Adachi Y Sasaki T Tabei T Ikeda Y Takatsuka 2002 Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer Ann Oncol 14 62 70
20. JF Robertson CK Osborne A Howell SE Jones L Mauriac M Ellis 2003 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials Cancer 98 2 229 238
21. A Howell JF Robertson AJ Quaresma A Aschermannova L Mauriac UR Kleeberg 2002 Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment J Clin Oncol 20 16 3396 3403
22. CK Osborne J Pippen SE Jones LM Parker M Ellis S Come 2002 Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J Clin Oncol 20 16 3386 3395
23. A Buzdar W Jonat A Howell SE Jones CP Blomqvist CL Vogel 1998 Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma Am Cancer Soc 83 1142 1152
24. A Buzdar SE Jones CL Vogel J Wolter P Plourde A Webster 1997 A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma Am Cancer Soc 79 730 739
25. JN Ingle VJ Suman KM Rowland D Mirchandani AM Bernath JK Camoriano 2006 Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032 J Clin Oncol 24 7 1052 1056
26. J O'Shaughnessy D Miles S Vukelja V Moiseyenko JP Ayoub G Cervantes 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 12 2812 2823
27. JL Blum V Dieras PM Lo Russo J Horton O Rutman A Buzdar 2001 Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 7 1759 1768
28. ROTE LISTE® (2007) German drug list (including EU approvals and specific medicinal products). www.rote-liste.de/
29. Einheitlicher Bewertungsmaßstab (2007) http://www.ebm2000plus.d
30. Albert U-S et al (2008) Stufe-3-Leitlinie Brustkrebs-Früherkennung in Deutschland. 1. Aktualisierung 2008. W Zuckschwerdt Verlag, München
31. Gold MR (1996) Cost-effectiveness in health and medicine. Oxford University Press, New York
32. Cameron DA, Camidge DR, Gait CF, Hirsch M (2006) Fulvestrant in the treatment of hormone receptor-positive advanced breast cancer-a cost-effective addition to the treatment sequence. Breast Cancer Res Treat 100(Supplement 1, S231)
33. Drummond MF et al (2005) Methods for the economic evaluation of health care programmes. Cost-effectiveness analysis, 3rd edn. OUP, Oxford, pp 103-136
34. CA Uyl-de Groot 2006 Economic evaluation of cancer therapies: more and better studies will lead to better choices in cancer care Eur J Cancer 42 17 2862 2866
35. Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister (2008) http://www.krebsgesellschaft.de/krebsregister,11268.html
36. A Howell JF Robertson P Abram MR Lichinitser R Elledge E Bajetta 2004 Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial J Clin Oncol 22 9 1605 1613
37. A Howell J Pippen RM Elledge L Mauriac I Vergote SE Jones 2005 Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials Cancer 104 2 236 239
38. A Howell 2007 Development of endocrine therapy of breast cancer 1896-2006 Geburtshilfe Frauenheilkd 67 595 601
39. DJ DeFriend A Howell RI Nicholson E Anderson M Dowsett RE Mansel 1994 Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer Cancer Res 54 2 408 414
40. A Howell 1996 New endocrine treatment strategies Eur J Cancer 5 3 2
41. M Warm R Kates F Overkamp SG Zaun N Harbeck 2009 Results of the German fulvestrant in practice evaluation programme to evaluate the efficacy, safety, tolerability and acceptance of fulvestrant under daily routine conditions Cancer Res 69 Suppl 399s
42. Cameron DA, Camidge DR, Gait CF, Hirsch M (2006) Fulvestrant in the treatment of hormone receptor-positive advanced breast cancer-a cost-effective addition to the treatment sequence. 29th Annual San Antonio breast cancer symposium, San Antonio, Texas, 14th-17th December 2006